Sumitomo Pharma Co., Ltd.: Attention Deficit Disorder with Hyperactivity trials

The registry lists 11 Attention Deficit Disorder with Hyperactivity studies with Sumitomo Pharma Co., Ltd. as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 2Phase 3 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.CompletedNCT03231800Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.CompletedNCT02734693Phase 3Results posted
• Dasotraline Pediatric Extension StudyCompletedNCT02457819Phase 3Results posted
• Adult Attention Deficit Hyperactivity DisorderCompletedNCT01692782Phase 2Results posted
• Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated InsomniaCompletedNCT00857220Phase 3Results posted
• Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated InsomniaCompletedNCT00856973Phase 3Results posted
• Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver DysfunctionCompletedNCT02795637Phase 1
• Dasotraline Pediatric ADHD StudyCompletedNCT02428088Phase 2/3
• Dasotraline Adult ADHD StudyCompletedNCT02276209Phase 3
• Dasotraline SEP360-105 Pediatric PK/PD StudyCompletedNCT02195167Phase 1
• Open-label Safety Study in Adults With ADHDCompletedNCT02160262Phase 3